Donata Vitagliano

2.2k total citations
29 papers, 1.9k citations indexed

About

Donata Vitagliano is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Donata Vitagliano has authored 29 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Donata Vitagliano's work include Cancer-related Molecular Pathways (10 papers), Thyroid Cancer Diagnosis and Treatment (9 papers) and Colorectal Cancer Treatments and Studies (5 papers). Donata Vitagliano is often cited by papers focused on Cancer-related Molecular Pathways (10 papers), Thyroid Cancer Diagnosis and Treatment (9 papers) and Colorectal Cancer Treatments and Studies (5 papers). Donata Vitagliano collaborates with scholars based in Italy, United States and United Kingdom. Donata Vitagliano's co-authors include Fortunato Ciardiello, Alfredo Fusco, Francesca Carlomagno, Giancarlo Vecchio, Teresa Guida, Massimo Santoro, Anderson J. Ryan, Giampaolo Tortora, Teresa Troiani and Floriana Morgillo and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer Research and Oncogene.

In The Last Decade

Donata Vitagliano

29 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donata Vitagliano Italy	19	1.0k	920	587	390	235	29	1.9k
Teresa Guida Italy	14	772 0.7×	858 0.9×	653 1.1×	327 0.8×	232 1.0×	18	1.8k
Fatima Rangwala United States	14	557 0.5×	618 0.7×	421 0.7×	284 0.7×	260 1.1×	34	1.6k
Vasyl Vasko United States	21	602 0.6×	659 0.7×	882 1.5×	169 0.4×	104 0.4×	38	1.7k
Anna L. Stratford Canada	24	567 0.5×	1.2k 1.3×	503 0.9×	130 0.3×	129 0.5×	27	1.9k
Roberto E. Favoni Italy	20	541 0.5×	844 0.9×	527 0.9×	356 0.9×	91 0.4×	39	1.6k
Todd G. Kroll United States	19	715 0.7×	1.5k 1.6×	1.3k 2.1×	159 0.4×	275 1.2×	23	2.8k
Lui Ng Hong Kong	19	676 0.6×	805 0.9×	224 0.4×	151 0.4×	118 0.5×	45	1.6k
Luis J. Leandro‐García Spain	20	532 0.5×	781 0.8×	315 0.5×	322 0.8×	73 0.3×	31	1.5k
Armelle Logié United Kingdom	19	442 0.4×	962 1.0×	206 0.4×	202 0.5×	161 0.7×	33	1.6k
Alexandra Eyzaguirre United States	8	564 0.5×	722 0.8×	255 0.4×	244 0.6×	101 0.4×	13	1.1k

Countries citing papers authored by Donata Vitagliano

Since Specialization

Citations

This map shows the geographic impact of Donata Vitagliano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donata Vitagliano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donata Vitagliano more than expected).

Fields of papers citing papers by Donata Vitagliano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donata Vitagliano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donata Vitagliano. The network helps show where Donata Vitagliano may publish in the future.

Co-authorship network of co-authors of Donata Vitagliano

This figure shows the co-authorship network connecting the top 25 collaborators of Donata Vitagliano. A scholar is included among the top collaborators of Donata Vitagliano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donata Vitagliano. Donata Vitagliano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bellelli, Roberto, Donata Vitagliano, Giorgia Federico, et al.. (2017). Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia. Molecular and Cellular Endocrinology. 460. 24–35. 12 indexed citations

Corte, Carminia Maria Della, Claudio Bellevicine, Giovanni Vicidomini, et al.. (2015). SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. Clinical Cancer Research. 21(20). 4686–4697. 97 indexed citations

Napolitano, Stefania, Giulia Martini, Barbara Rinaldi, et al.. (2015). Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. Clinical Cancer Research. 21(13). 2975–2983. 62 indexed citations

Troiani, Teresa, Stefania Napolitano, Giulia Martini, et al.. (2015). Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research. 21(18). 4153–4164. 14 indexed citations

Troiani, Teresa, Stefania Napolitano, Donata Vitagliano, et al.. (2014). Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research. 20(14). 3775–3786. 83 indexed citations

Morgillo, Floriana, Ferdinando Carlo Sasso, Carminia Maria Della Corte, et al.. (2013). Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research. 19(13). 3508–3519. 109 indexed citations

Troiani, Teresa, Erika Martinelli, Stefania Napolitano, et al.. (2013). Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research. 19(24). 6751–6765. 125 indexed citations

Martinelli, Erika, Teresa Troiani, Elena D’Aiuto, et al.. (2013). Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells. International Journal of Cancer. 133(9). 2089–2101. 83 indexed citations

Troiani, Teresa, Loredana Vecchione, Erika Martinelli, et al.. (2012). Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. British Journal of Cancer. 106(10). 1648–1659. 35 indexed citations

10.

Morgillo, Floriana, Carminia Maria Della Corte, Giulia Martini, et al.. (2012). Role of the Hedgehog Pathway in Mediating Resistance to Anti-Egfr Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer. Annals of Oncology. 23. ix430–ix430. 1 indexed citations

11.

Vitagliano, Donata, Valentina De Falco, Anna Tamburrino, et al.. (2010). The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine Related Cancer. 18(1). 1–11. 55 indexed citations

12.

Vitagliano, Donata, Giuseppe Portella, Giancarlo Troncone, et al.. (2006). Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene. 25(39). 5467–5474. 58 indexed citations

13.

Vitagliano, Donata, Francesca Carlomagno, Maria Letizia Motti, et al.. (2004). Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells. Cancer Research. 64(11). 3823–3829. 41 indexed citations

14.

Celetti, Angela, Aniello Cerrato, Francesco Merolla, et al.. (2004). H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene. 23(1). 109–121. 49 indexed citations

15.

Carlomagno, Francesca, Donata Vitagliano, Teresa Guida, et al.. (2003). Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2). The Journal of Clinical Endocrinology & Metabolism. 88(4). 1897–1902. 96 indexed citations

16.

Carlomagno, Francesca, Donata Vitagliano, Teresa Guida, et al.. (2002). ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.. PubMed. 62(24). 7284–90. 481 indexed citations

17.

Portella, Giuseppe, Stefania Scala, Donata Vitagliano, Giancarlo Vecchio, & Alfredo Fusco. (2002). ONYX-015, an E1B Gene-Defective Adenovirus, Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines. The Journal of Clinical Endocrinology & Metabolism. 87(6). 2525–2531. 49 indexed citations

18.

Scala, Stefania, Giuseppe Portella, Donata Vitagliano, et al.. (2001). HMGI-C gene expression is not required for in vivo thyroid cell transformation. Carcinogenesis. 22(2). 251–256. 8 indexed citations

19.

Portella, Giuseppe, Donata Vitagliano, Cristina Borselli, et al.. (1999). Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells.. PubMed. 11(9). 421–7. 31 indexed citations

20.

Sage, J. I., M. H. Mark, Denise M. McHale, Patricia K. Sonsalla, & Donata Vitagliano. (1991). Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug‐induced chorea. Annals of Neurology. 29(6). 623–628. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact